Xspray Pharma: Raising cash and ongoing inspection of manufacturing facilities - Redeye

Xspray Pharma: Raising cash and ongoing inspection of manufacturing facilities - Redeye

The FDA has started a follow-up inspection at NerPharMa, the main obstacle to approval of Dasynoc and Nilopki. At the same time, in conjunction with the Q3 release Xspray is raising up to SEK162m, aimed at securing funding through expected approvals.

Länk till analysen i sin helhet: https://www.redeye.se/research/1191734/xspray-pharma-raising-cash-and-ongoing-inspection-of-manufacturing-facilities?utm_source=finwire&utm_medium=RSS